These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 33162995)

  • 21. Inhibition of Bruton's TK regulates macrophage NF-κB and NLRP3 inflammasome activation in metabolic inflammation.
    Purvis GSD; Collino M; Aranda-Tavio H; Chiazza F; O'Riordan CE; Zeboudj L; Mohammad S; Collotta D; Verta R; Guisot NES; Bunyard P; Yaqoob MM; Greaves DR; Thiemermann C
    Br J Pharmacol; 2020 Oct; 177(19):4416-4432. PubMed ID: 32608058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Macrophage effector functions controlled by Bruton's tyrosine kinase are more crucial than the cytokine balance of T cell responses for microfilarial clearance.
    Mukhopadhyay S; Mohanty M; Mangla A; George A; Bal V; Rath S; Ravindran B
    J Immunol; 2002 Mar; 168(6):2914-21. PubMed ID: 11884462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
    Joseph RE; Amatya N; Fulton DB; Engen JR; Wales TE; Andreotti A
    Elife; 2020 Nov; 9():. PubMed ID: 33226337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new molecular genetic diagnosis of the Btk(xid) mice.
    Takagi Y; Masui N; Yasuda M; Ono S
    Exp Anim; 2007 Jan; 56(1):63-6. PubMed ID: 17283893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NLRP3 inflammasome and bruton tyrosine kinase inhibition interferes with upregulated platelet aggregation and in vitro thrombus formation in sickle cell mice.
    Vogel S; Kamimura S; Arora T; Smith ML; Almeida LEF; Combs CA; Thein SL; Quezado ZMN
    Biochem Biophys Res Commun; 2021 May; 555():196-201. PubMed ID: 33831782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
    Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY
    Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bruton's Tyrosine Kinase Deficiency Ameliorates Antimicrobial Host Defense during Peritonitis Induced by Pathogenic Escherichia coli.
    Liu Z; van 't Veer C; Hendriks RW; Roelofs JJTH; van der Poll T; de Vos AF
    Infect Immun; 2022 Jun; 90(6):e0067421. PubMed ID: 35587199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bruton's agammaglobulinemia tyrosine kinase (Btk) regulates TPA‑induced breast cancer cell invasion via PLCγ2/PKCβ/NF‑κB/AP‑1‑dependent matrix metalloproteinase‑9 activation.
    Kim JM; Park J; Noh EM; Song HK; Kang SY; Jung SH; Kim JS; Park BH; Lee YR; Youn HJ
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bruton's Tyrosine Kinase Inhibitor Attenuates Warm Hepatic Ischemia/Reperfusion Injury via Modulation of the NLR Family Pyrin Domain Containing 3 Inflammasome.
    Song SH; Liu F; Zhao YY; Sun KY; Guo M; Li PL; Liu H; Ding GS; Fu ZR
    Transplant Proc; 2020 Dec; 52(10):2947-2954. PubMed ID: 33131902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity.
    Bittner ZA; Liu X; Mateo Tortola M; Tapia-Abellán A; Shankar S; Andreeva L; Mangan M; Spalinger M; Kalbacher H; Düwell P; Lovotti M; Bosch K; Dickhöfer S; Marcu A; Stevanović S; Herster F; Cardona Gloria Y; Chang TH; Bork F; Greve CL; Löffler MW; Wolz OO; Schilling NA; Kümmerle-Deschner JB; Wagner S; Delor A; Grimbacher B; Hantschel O; Scharl M; Wu H; Latz E; Weber ANR
    J Exp Med; 2021 Nov; 218(11):. PubMed ID: 34554188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. X-linked immunodeficient mice exhibit enhanced susceptibility to Cryptococcus neoformans Infection.
    Szymczak WA; Davis MJ; Lundy SK; Dufaud C; Olszewski M; Pirofski LA
    mBio; 2013 Jul; 4(4):. PubMed ID: 23820392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase.
    Liu X; Pichulik T; Wolz OO; Dang TM; Stutz A; Dillen C; Delmiro Garcia M; Kraus H; Dickhöfer S; Daiber E; Münzenmayer L; Wahl S; Rieber N; Kümmerle-Deschner J; Yazdi A; Franz-Wachtel M; Macek B; Radsak M; Vogel S; Schulte B; Walz JS; Hartl D; Latz E; Stilgenbauer S; Grimbacher B; Miller L; Brunner C; Wolz C; Weber ANR
    J Allergy Clin Immunol; 2017 Oct; 140(4):1054-1067.e10. PubMed ID: 28216434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bruton's tyrosine kinase inhibition attenuates disease progression by reducing renal immune cell invasion in mice with hemolytic-uremic syndrome.
    Kröller S; Wissuwa B; Dennhardt S; Krieg N; Thiemermann C; Daniel C; Amann K; Gunzer F; Coldewey SM
    Front Immunol; 2023; 14():1105181. PubMed ID: 36911665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complementary roles for CD19 and Bruton's tyrosine kinase in B lymphocyte signal transduction.
    Fujimoto M; Poe JC; Satterthwaite AB; Wahl MI; Witte ON; Tedder TF
    J Immunol; 2002 Jun; 168(11):5465-76. PubMed ID: 12023340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile.
    Barf T; Covey T; Izumi R; van de Kar B; Gulrajani M; van Lith B; van Hoek M; de Zwart E; Mittag D; Demont D; Verkaik S; Krantz F; Pearson PG; Ulrich R; Kaptein A
    J Pharmacol Exp Ther; 2017 Nov; 363(2):240-252. PubMed ID: 28882879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bruton tyrosine kinase deficiency augments NLRP3 inflammasome activation and causes IL-1β-mediated colitis.
    Mao L; Kitani A; Hiejima E; Montgomery-Recht K; Zhou W; Fuss I; Wiestner A; Strober W
    J Clin Invest; 2020 Apr; 130(4):1793-1807. PubMed ID: 31895698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bruton's tyrosine kinase regulates macrophage‑induced inflammation in the diabetic kidney via NLRP3 inflammasome activation.
    Zhao J; Chen J; Li YY; Xia LL; Wu YG
    Int J Mol Med; 2021 Sep; 48(3):. PubMed ID: 34278465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
    Ran F; Liu Y; Wang C; Xu Z; Zhang Y; Liu Y; Zhao G; Ling Y
    Eur J Med Chem; 2022 Feb; 229():114009. PubMed ID: 34839996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI.
    Nicolson PLR; Hughes CE; Watson S; Nock SH; Hardy AT; Watson CN; Montague SJ; Clifford H; Huissoon AP; Malcor JD; Thomas MR; Pollitt AY; Tomlinson MG; Pratt G; Watson SP
    Haematologica; 2018 Dec; 103(12):2097-2108. PubMed ID: 30026342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.